Diabetes — all decisions

The Board remands the claims for service connection for diabetes mellitus and prostate cancer due to insufficient evidence regarding the Veteran's exposure to herbicide agents in the Korean DMZ.

The Board remands the claims for an increased rating of diabetes mellitus II and entitlement to TDIU prior to June 15, 2018, due to a lack of compliance with previous remand directives.

The Board denied the veteran's claims for higher ratings and earlier effective dates, except for an earlier effective date for service connection of lower extremity peripheral neuropathy.

The appeal for service connection for sinusitis was denied, while the other claims were remanded for further development.

The Board granted service connection for obstructive sleep apnea (OSA) as it was caused by the Veteran's service-connected acquired psychiatric disorder. The other claims for type 2 diabetes mellitus, hypertension, and irritable bowel syndrome were remanded for further examination.

The Board is remanding the claim for service connection of the Veteran's cause of death due to a predecisional duty to assist error in not obtaining relevant medical records from the state veteran's home.

The Board granted service connection for diabetes mellitus type II, finding that the Veteran's service-connected depressive disorder caused his obesity, which in turn led to the development of diabetes.

The Board denied service connection for hypertension and diabetes mellitus as there is no evidence of in-service incurrence or continuity of symptoms since service, nor any medical opinion linking the conditions to active duty.

The Board remands the claims for service connection for atrial fibrillation, arteriosclerosis, diabetes, and hypertension as additional evidence has been submitted that requires further development of the record.

The Board remands the claims for service connection for diabetes mellitus type II and atherosclerotic heart disease to obtain additional evidence, as the Veteran's service treatment records are unavailable and there is insufficient medical evidence to determine the etiology of these conditions.

The Board granted effective dates of August 4, 2021, for several conditions and denied or remanded claims related to other issues.

The Veteran was granted an earlier effective date of October 8, 2021, for the grant of service connection for hypothyroidism based on direct service connection. The claims for OSA and diabetes mellitus were remanded.

The Board granted service connection for diabetes mellitus Type 2 and sleep apnea, resolving reasonable doubt in the Veteran's favor.

The Board granted service connection for ischemic heart disease and diabetes mellitus type II, both presumed to be related to exposure to herbicides during ACDUTRA at Fort McClellan. The claims for benign prostatic hyperplasia, headaches, and skin cancer were remanded.

The Board remands the claims for service connection for diabetes mellitus, type II, gastrointestinal cancer, hypertension, and prostate cancer to correct a duty to assist error related to verifying herbicide agent exposure.

The appeal was dismissed due to the Veteran's death while it was pending.

The Board granted a separate initial rating of 10 percent for hypertension (as a complication of diabetes) effective November 17, 2023, and denied ratings in excess of the current levels for diabetes mellitus with retinopathy and gastroparesis, neuropathy of the left foot, and entitlement to a total disability rating due to individual unemployability.

The Board granted service connection for diabetes mellitus type II, hypertension, chronic kidney disease, anemia, and eye disability as secondary to the Veteran's service-connected bilateral knee disabilities.

The Board denied an initial disability rating greater than 30 percent for PTSD and remanded the claims for service connection for obstructive sleep apnea, diabetes mellitus, type II, syncope, and a compensable initial disability rating for chronic obstructive pulmonary disease (COPD).

The appeals for service connection for atherosclerotic cardiovascular disease, carotid disease, chronic kidney disease, COPD, and type 2 diabetes mellitus are dismissed as moot.